Authorized Generics as a Manufacturer Response to the Medicaid Rebate Cap Removal

Zeid S. El-Kilani; Sanika Kulkarni; Joseph F. Levy

doi:10.1001/jamahealthforum.2026.0680

Authorized Generics as a Manufacturer Response to the Medicaid Rebate Cap Removal

Zeid S. El-Kilani
, Sanika Kulkarni
, Joseph F. Levy

Bloomberg School of Public Health

Research output: Contribution to journal › Article › peer-review

Abstract

This cross-sectional study assesses the utilization of branded vs generic dapagliflozin and the financial implications of switching to generics under the Medicaid fee-for-service and managed care organization payment structures.

Original language	English (US)
Article number	e260680
Journal	JAMA Health Forum
Volume	7
Issue number	5
DOIs	https://doi.org/10.1001/jamahealthforum.2026.0680
State	Published - May 8 2026

ASJC Scopus subject areas

Health Policy
Public Health, Environmental and Occupational Health

Access to Document

10.1001/jamahealthforum.2026.0680

Cite this

@article{0b84139c027d46d8a46e75064958d1d6,

title = "Authorized Generics as a Manufacturer Response to the Medicaid Rebate Cap Removal",

abstract = "This cross-sectional study assesses the utilization of branded vs generic dapagliflozin and the financial implications of switching to generics under the Medicaid fee-for-service and managed care organization payment structures.",

author = "El-Kilani, \{Zeid S.\} and Sanika Kulkarni and Levy, \{Joseph F.\}",

note = "Publisher Copyright: {\textcopyright} 2026 El-Kilani ZS et al.",

year = "2026",

month = may,

day = "8",

doi = "10.1001/jamahealthforum.2026.0680",

language = "English (US)",

volume = "7",

journal = "JAMA Health Forum",

issn = "2689-0186",

publisher = "American Medical Association",

number = "5",

}

TY - JOUR

T1 - Authorized Generics as a Manufacturer Response to the Medicaid Rebate Cap Removal

AU - El-Kilani, Zeid S.

AU - Kulkarni, Sanika

AU - Levy, Joseph F.

PY - 2026/5/8

Y1 - 2026/5/8

N2 - This cross-sectional study assesses the utilization of branded vs generic dapagliflozin and the financial implications of switching to generics under the Medicaid fee-for-service and managed care organization payment structures.

AB - This cross-sectional study assesses the utilization of branded vs generic dapagliflozin and the financial implications of switching to generics under the Medicaid fee-for-service and managed care organization payment structures.

UR - https://www.scopus.com/pages/publications/105038373060

UR - https://www.scopus.com/pages/publications/105038373060#tab=citedBy

U2 - 10.1001/jamahealthforum.2026.0680

DO - 10.1001/jamahealthforum.2026.0680

M3 - Article

C2 - 42101855

AN - SCOPUS:105038373060

SN - 2689-0186

VL - 7

JO - JAMA Health Forum

JF - JAMA Health Forum

IS - 5

M1 - e260680

ER -

Authorized Generics as a Manufacturer Response to the Medicaid Rebate Cap Removal

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this